Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Saturday, August 13, 2022

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Molderizer and Safe Shield

Common autoimmune drugs reduce mortality, up clinical status in COVID-19: NIH

Workers without paid leave lost $28 billion in wages during Covid-19

Families, parents and caregivers call on Congress to include paid family and medical leave in the Build Back Better legislative package during an...

OHSU coronavirus (COVID-19) response | OHSU News

Aerial of OHSU. (OHSU/Aaron Bieleck) As of Friday, August 12 Patients hospitalized with COVID-19 OHSU: 21 Hillsboro Medical Center: 4 OHSU Hospital and OHSU...

42 Illinois counties at “high” risk for COVID-19; 17 fewer counties than last week – Shaw Local

The Illinois Department of Public Health announced Friday that 42 counties in the state are considered “high” risk for COVID-19, down from 59 a week...


A sick nursing home resident lies in bed



Two commonly used autoimmune drugs cut deaths and substantially improved clinical status in adults with COVID-19, a large clinical trial led by the National Institutes of Health has found. The medications could be used in addition to standard-of-care treatments to improve outcomes, the agency says.

Investigators treated hospitalized patients with infliximab (Remicade) and abatacept (Orencia) to determine whether the drugs reduced the risk of overactive immune responses that can lead to life-threatening complications. 

When compared to placebo, patients given Remicade had 40% lower odds of dying and 44% greater odds of clinical improvement. In the Orencia trail group, risk of death was reduced by 37% and the likelihood of clinical improvement rose by 34%, investigators reported. The drugs did not appear to speed recovery time, however.

“When given in addition to standard-of-care treatments, like remdesivir and dexamethasone, infliximab and abatacept each offered a substantial reduction in mortality,” said the trial’s protocol chair, William G. Powderly, M.D., of Washington University School of Medicine in St. Louis. “These drugs could potentially add to the therapeutic options available for the treatment of patients hospitalized with COVID-19.”

The trial is part of a broader public-private initiative to see if certain existing drugs will help shorten recovery times and reduce deaths by lessening the effects of immune response in COVID-19. Infliximab and abatacept are widely used to treat autoimmune diseases such as rheumatoid arthritis and ulcerative colitis by reducing inflammation.

In certain cases, COVID-19 spurs what’s called a cytokine storm, the release of excessive amounts of proteins. This in turn triggers inflammation, leading to complications such as acute respiratory distress syndrome and multiple organ failure. 

Related articles:

Remdesivir cuts risk of severe COVID-19 by 87% in non-hospitalized patients

25 percent of COVID-19 patients have post-acute symptoms; Report highlights emerging care needs

FDA OKs first injectable antibody drug to prevent COVID-19 in high-risk patients



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Workers without paid leave lost $28 billion in wages during Covid-19

Families, parents and caregivers call on Congress to include paid family and medical leave in the Build Back Better legislative package during an...

OHSU coronavirus (COVID-19) response | OHSU News

Aerial of OHSU. (OHSU/Aaron Bieleck) As of Friday, August 12 Patients hospitalized with COVID-19 OHSU: 21 Hillsboro Medical Center: 4 OHSU Hospital and OHSU...

42 Illinois counties at “high” risk for COVID-19; 17 fewer counties than last week – Shaw Local

The Illinois Department of Public Health announced Friday that 42 counties in the state are considered “high” risk for COVID-19, down from 59 a week...

Related Articles

Workers without paid leave lost $28 billion in wages during Covid-19

Families, parents and caregivers call on Congress to include paid family and medical leave in the Build Back Better legislative package during an...

OHSU coronavirus (COVID-19) response | OHSU News

Aerial of OHSU. (OHSU/Aaron Bieleck) As of Friday, August 12 Patients hospitalized with COVID-19 OHSU: 21 Hillsboro Medical Center: 4 OHSU Hospital and OHSU...

42 Illinois counties at “high” risk for COVID-19; 17 fewer counties than last week – Shaw Local

The Illinois Department of Public Health announced Friday that 42 counties in the state are considered “high” risk for COVID-19, down from 59 a week...